For the injectable and topical testosterone used in standard replacement therapy, liver injury is not the main concern, and the kidneys are mostly a lab-interpretation issue. The liver warning people remember belongs to a different drug class: older oral androgens that were chemically modified (17-alpha-alkylated) to survive digestion. The American Urological Association (AUA) guideline tells clinicians not to prescribe alkylated oral testosterone.
That said, “uncommon” is not the same as “never check.” Here is what the labels, guidelines and reference sources say, and what monitoring is for.
Where the liver fear comes from
The NIH LiverTox reference on androgenic steroids says 17-alpha-alkylated androgens such as methyltestosterone, oxymetholone and stanozolol have all been implicated in cases of liver injury. It describes four patterns: transient enzyme elevations, cholestasis (blocked bile flow, estimated in about 1 percent of patients on several of these agents), peliosis hepatis, and liver tumors, which it says are typically found after 5 to 15 years of use. Alkylation is what allows oral dosing by slowing the liver’s breakdown of the drug.
The same reference says testosterone esters (cypionate, enanthate, propionate) have only rarely been implicated in cholestasis, that long-term use may raise tumor risk but at a lower rate than with alkylated agents, and that cholestasis has not been described with unmodified testosterone given by injection or patch. Our explainer on the ester difference shows how the common injectable esters work.
FDA labeling says the same thing in regulatory language. The Depo-Testosterone (testosterone cypionate) label states that prolonged high-dose use of 17-alpha-alkyl androgens has been associated with hepatic adenomas, hepatocellular carcinoma and peliosis hepatis. It also lists alterations in liver function tests as an adverse reaction and lists serious cardiac, hepatic or renal disease among its contraindications, so existing organ disease is something your prescriber must know about.
What about modern oral testosterone?
Oral testosterone undecanoate is not an alkylated androgen. The Jatenzo label notes the liver risk of high-dose oral 17-alpha-alkyl androgens and states that Jatenzo is not known to cause those adverse effects, while still telling prescribers to stop the drug if jaundice or other liver dysfunction occurs. The same label lists blood pressure increases under its Warnings and Precautions; its boxed warning was removed in July 2025. In February 2025 the FDA asked for increased-blood-pressure warnings across all testosterone products, based on blood pressure monitoring studies. See the oral testosterone comparison and ask your prescriber about the labeling for any product you use.
What the labs check
Liver and kidney markers usually come bundled in a comprehensive metabolic panel (CMP), a routine blood test.
| Marker | What it reflects | Why it appears on a TRT panel |
|---|---|---|
| ALT and AST | Liver cell irritation | Baseline and follow-up screen; also flags fatty liver, alcohol effects and medicine reactions |
| Alkaline phosphatase and bilirubin | Bile flow | Helps spot cholestasis or other liver issues |
| Creatinine and eGFR | Kidney filtration estimate | Baseline kidney function and trend |
| BUN and electrolytes | Kidney and hydration status | Context for the above |
Some everyday things can move these numbers without harm. Very hard training shortly before a draw, dehydration and some supplements are common examples, so mention them to whoever reads your labs. The more specific monitoring items in the sources we read are hematocrit, prostate assessment and blood pressure; the Testim label, for example, calls for a hematocrit check before starting, at 3 to 6 months and then yearly. See how to read TRT bloodwork.
The kidney question
Kidney evidence in men on standard TRT is thinner than the liver reference material. Three things we can say from sources we read:
- A trial signal. The TRAVERSE abstract (5,246 men aged 45 to 80 with existing or high risk of heart disease) reported a higher incidence of acute kidney injury, along with atrial fibrillation and pulmonary embolism, in the testosterone group. The text we read did not give event counts, so ask your prescriber how this applies to your history.
- Fluid retention. The Depo-Testosterone label says edema may be a serious complication in patients with pre-existing cardiac, renal or hepatic disease.
- Creatinine can rise for non-kidney reasons. A 2025 meta-analysis of 20 observational studies of testosterone-based gender-affirming therapy (a different population from men treated for hypogonadism) found creatinine rose and creatinine-based eGFR dipped in the first year, then stabilized. The authors attributed this mainly to muscle gain rather than kidney impairment, pointing to stable BUN, but noted no included study measured cystatin C, a marker less affected by muscle mass.
If creatinine edges up after you start, your clinician can check other markers such as cystatin C or urine tests before drawing conclusions. Men with existing kidney disease, uncontrolled blood pressure or heart failure need a prescriber who knows their full history before starting.
Other things that stress the liver and kidneys
- Alcohol. Heavy drinking is a common cause of abnormal liver tests in its own right. See TRT and alcohol.
- Supplements. Supplements are not tested like drugs, and quality varies. Tell your prescriber about everything you take. See our ashwagandha article.
- Anti-inflammatory painkillers. Regular high use of NSAIDs can strain the kidneys, independent of any hormone.
- Gray-market products. The Jatenzo label states that androgen abuse can cause serious cardiac, hepatic and psychiatric reactions, and unregulated sources cannot be checked against a label. See the risks of gray-market testosterone.
- Dehydration and thick blood. These can show up on kidney labs and hematocrit. See hematocrit and TRT.
When to call a doctor
Get prompt medical advice for yellowing of the skin or eyes, very dark urine, pale stools, persistent right-upper abdominal pain, unexplained itching, marked swelling in the legs or face, or a big drop in urine output. Do not wait for your next scheduled lab.
Bottom line
The liver warnings that circulate online belong mostly to alkylated oral androgens, which the AUA says should not be prescribed. Esters and unmodified testosterone are associated with far fewer liver problems in the NIH reference, though labels still list liver tests and organ disease as things to watch. For the kidneys, a creatinine bump may reflect muscle, but a trial signal and the edema warning are reasons to keep monitoring. A baseline panel, repeat labs on your prescriber’s schedule and an honest supplement list do most of the work.
Frequently Asked Questions
Is injectable testosterone toxic to the liver?
Liver injury from testosterone esters such as cypionate and enanthate is rarely reported, according to the NIH LiverTox reference. The well-documented liver problems are linked to 17-alpha-alkylated oral androgens, which are a different drug class. Your prescriber still checks liver tests as part of monitoring.
Why did my creatinine go up after I started TRT?
Creatinine partly reflects muscle mass, and testosterone therapy can add muscle. A modest rise does not always mean kidney damage. Your clinician can confirm with other tests such as cystatin C or a urine test.
Which blood tests check liver and kidney health on TRT?
A comprehensive metabolic panel covers ALT, AST, bilirubin, alkaline phosphatase, creatinine and eGFR. Your prescriber decides how often to repeat it based on your history.
Can I take TRT if I have kidney or liver disease?
It depends on the condition and its severity. The Depo-Testosterone label lists serious cardiac, hepatic or renal disease as a contraindication, so this is a decision for a clinician who knows your full history, often with input from a specialist. Do not start treatment without that evaluation.
Do supplements matter for liver safety on TRT?
Yes. Supplement quality control varies, and some products can affect the liver or kidneys. Tell your prescriber about every supplement, especially before bloodwork.
Sources and verification note
Checked October 2026. We opened and read each of these pages. Points we could not confirm from a source we read, such as how exercise or supplements shift routine lab values, are described only in general terms.
- NIH LiverTox, Androgenic Steroids
- American Urological Association, Evaluation and Management of Testosterone Deficiency guideline (statement on alkylated oral testosterone)
- FDA labels: Depo-Testosterone, Jatenzo, Testim (2025 revisions)
- FDA, FDA issues class-wide labeling changes for testosterone products (February 2025)
- Lincoff AM, et al., N Engl J Med 2023, TRAVERSE (abstract content)
- Tienforti D, et al., Front Endocrinol 2025, Effects of gender affirming hormone therapy with testosterone on renal function: a meta-analysis (different population; observational studies)
Educational only; not medical advice. Review liver and kidney results with the clinician who manages your therapy.
Monitoring Is the Real Safeguard
Organ-safety questions are answered by routine labs and an honest medication list, not by guesswork. Make sure whoever manages your therapy reviews liver and kidney markers and knows everything else you take.
Compare Vetted TRT Clinics →This article is for informational purposes only and does not constitute medical advice. Always consult a licensed physician about testosterone therapy.